Company news

Harmony Biosciences Holdings, Inc. news in 2025

Harmony Biosciences Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

December 7, 2025

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

December 1, 2025

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

November 23, 2025

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

November 18, 2025

Harmony Biosciences to Participate in Upcoming Investor Conferences

November 17, 2025

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

November 3, 2025

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

October 22, 2025

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

September 23, 2025

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

August 25, 2025

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

August 20, 2025

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

August 4, 2025

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

July 21, 2025

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

July 14, 2025

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

June 10, 2025

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

June 4, 2025

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

May 5, 2025

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

April 28, 2025

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

April 7, 2025

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

April 2, 2025

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

March 25, 2025

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

March 23, 2025

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

February 24, 2025

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

February 18, 2025

Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

February 17, 2025

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

January 12, 2025

Calls in 2025

Decks in 2025